LEI:
549300Q7EXQQH6KF7Z84
03 October
2024
RTW Biotech Opportunities
Ltd
Launch of Obesity Company Kailera
Therapeutics
RTW Biotech Opportunities Ltd (the "Company"), a
London Stock Exchange-listed investment company focused on
identifying transformative assets with high growth potential across
the life sciences sector, is pleased to note the announcement by
new portfolio company, Kailera
Therapeutics ("Kailera"), of its launch and $400 million
Series A financing round co-led by RTW Investments (the
"Investment
Manager").
The Company, alongside other
investment vehicles managed by RTW Investments, co-led the
Series A with Atlas Venture and Bain Capital Life Sciences, with
participation from Lyra Capital. The funding will be used to
advance a portfolio of next-generation therapies for obesity and
related conditions.
Kailera's mission is to develop
next-generation weight management therapies that give people the
power to transform their lives and elevate their overall
health. It is developing a broad, advanced, and differentiated
portfolio of clinical-stage injectable and oral therapies
that have demonstrated potential as best-in-class
treatments for the treatment of chronic
weight management. Kailera's most advanced program, KAI-9531, is an
injectable GLP-1/GIP receptor dual agonist that demonstrated
positive results in Phase 2 trials in obesity and type 2 diabetes
in China.
Roderick Wong,
Managing Partner and CIO at the
Investment Manager commented on the launch, "We are immensely proud
to co-lead the Series A launch of Kailera Therapeutics, our fourth
new company creation at RTW. Kailera represents a significant step
forward in addressing the huge market for chronic weight management
and metabolic diseases. With its clinically-validated pipeline and
experienced management team, we are confident that Kailera is
well-positioned to develop breakthrough therapies that will
profoundly improve the lives of patients worldwide. We look forward
to supporting them on this transformative journey."
The full text of the announcement can be
accessed
here.
For Further
Information
|
RTW
Investments, LP
|
+44
20 7959 6361
|
|
Woody Stileman, Managing Director,
Business Development
Krisha McCune, Director, Investor
Relations
|
biotechopportunities@rtwfunds.com
|
|
Buchanan (PR & Communications Adviser)
|
+44
20 7466 5107
|
|
Charles Ryland
|
|
|
Henry Wilson
|
|
|
George Beale
|
|
|
Deutsche Numis (Joint Corporate Broker)
Freddie Barnfield
|
+44
20 7260 1000
|
|
Nathan Brown
|
|
|
Euan Brown
|
|
|
BofA Securities (Joint Corporate Broker)
|
+44
20 7628 1000
|
|
Edward Peel
|
|
|
Alex Penney
|
|
|
Cadarn Capital (Distribution & IR
Partner)
|
+44
73 6888 3211
|
|
David Harris
|
|
|
Elysium Fund Management Limited
Joanna Duquemin Nicolle, Chief
Executive Officer
Sadie Morrison, Managing
Director
|
+44 14 8170 3100
|
|
Morgan Stanley Fund Services USA LLC
|
+1
914 225 8885
|
|
|
|
About Biotech Opportunities Ltd:
RTW Biotech Opportunities Ltd (LSE:
RTW) is an investment fund focused on identifying transformative
assets with high growth potential across the biopharmaceutical and
medical technology sectors. Driven by a long-term approach to
support innovative businesses, RTW Biotech Opportunities Ltd
invests in companies developing next-generation therapies and
technologies that can significantly improve patients' lives. RTW
Biotech Opportunities Ltd is managed by RTW Investments, LP, a
leading healthcare-focused
entrepreneurial investment firm with
deep scientific expertise and a strong track record of supporting
companies developing life-changing therapies.
Visit the website
at www.rtwfunds.com/rtw-biotech-opportunities-ltd for
more information.
***********
The information in this announcement
may include forward-looking statements, which are based on the
current expectations and projections about future events, and in
certain cases can be identified by the use of terms such as "may",
"will", "should", "expect", "anticipate", "project", "estimate",
"intend", "continue", "target", "believe" (or the negatives
thereon) or other variations thereon or comparable terminology.
These forward-looking statements, as well as those included in any
related materials, are subject to risks, uncertainties and
assumptions about the Company and/or its underlying investments,
including, among other things, the development of the applicable
entity's business, trends in its operating industry, expected use
of financing proceeds and future capital expenditures and
acquisitions. In light of these risks, uncertainties and
assumptions, the events in the forward-looking statements may not
occur.
The information contained in this
announcement is given at the date of its publication (unless
otherwise marked). No reliance may be placed for any purpose
whatsoever on the information or opinions contained in this
announcement or on its completeness, accuracy or
fairness.
***********